Cargando…

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies—reply

Detalles Bibliográficos
Autores principales:	Albini, Adriana, Noonan, Douglas McClain, Pelosi, Giuseppe, Di Guardo, Giovanni, Lombardo, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Ce - Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360123/ https://www.ncbi.nlm.nih.gov/pubmed/32666177 http://dx.doi.org/10.1007/s11739-020-02436-7

Ejemplares similares

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies
por: Albini, Adriana, et al.
Publicado: (2020)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment
por: De Cauwer, Harald
Publicado: (2020)

Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
por: Ferrario, Carlos M., et al.
Publicado: (2020)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Amat-Santos, Ignacio J., et al.
Publicado: (2020)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers
por: Lee, Ivan T., et al.
Publicado: (2020)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?
por: Manga, Pravin
Publicado: (2020)

Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT(1) receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
por: Iwai, Masaru, et al.
Publicado: (2009)

ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death
por: Arora, Nayan, et al.
Publicado: (2020)

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
por: Trifirò, Gianluca, et al.
Publicado: (2020)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease
por: Labandeira, Carmen M., et al.
Publicado: (2022)

Angiotensin Converting Enzyme (ACE) and ACE2 Bind Integrins and ACE2 Regulates Integrin Signalling
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany
por: Rudolph, Ulrike Maria, et al.
Publicado: (2020)

Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2
por: Clayton, Daniel, et al.
Publicado: (2015)

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes
por: Benter, Ibrahim F., et al.
Publicado: (2013)

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women
por: Bea, Jennifer W., et al.
Publicado: (2018)

Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
por: LaClair, Heather J., et al.
Publicado: (2021)

Use of ß-blocker therapy to prevent primary bleeding of esophageal varices
por: Tursi, Tammy
Publicado: (2010)

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study
por: Parit, Rahul, et al.
Publicado: (2021)

Antihypertensive and cardiovascular effects of combined blockade of renin-angiotensin system with ACE inhibitor and angiotensin II type 1 receptor blocker in hypertensive patients: A 24-week randomized controlled double-dummy trial
por: ARGANO, CHRISTIANO, et al.
Publicado: (2006)

Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy
por: Malfertheiner, Peter, et al.
Publicado: (2018)

COVID-19 and ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury
por: GonzÃ¡lez-Rayas, JosÃ© Manuel, et al.
Publicado: (2020)

Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2021)

Recombinant human ACE2: acing out angiotensin II in ARDS therapy
por: Zhang, Haibo, et al.
Publicado: (2017)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma
por: Kim, Kihun, et al.
Publicado: (2020)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis
por: Albini, Adriana, et al.
Publicado: (2021)

The ACE2/Angiotensin-(1–7)/Mas Receptor Axis: Pleiotropic Roles in Cancer
por: Xu, Juanjuan, et al.
Publicado: (2017)

ACE2 and Diabetes: ACE of ACEs?
por: Batlle, Daniel, et al.
Publicado: (2010)

Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
por: Gómez, Juan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_10jshukg3sn0ejjqtjs6hoi9mb